Biodim lets NuPharm access French market
NuPharm has completed a deal to buy French firm Laboratoire Biodim from Weinberg Capital Partners’ Pharma Omnium International, for an undisclosed sum. “This strategic acquisition enables NuPharm to enter France and expand its European footprint,” the group observed, “into its fifth country after Germany, Spain, Italy and Poland.” Created in 2016, Nupharm was the result of combining five companies – Spain’s Qualigen, Laboratorios Lesvi and Inke; Germany’s Neuraxpharm, which also operates in Poland; and Italy’s FB Health – with investment group Apax Partners.
You may also be interested in...
Neuraxpharm has kicked off its operations in Poland with the appointment of Wojciech Góra as general manager of its new Neuraxpharm Polska business.
European CNS specialist Neuraxpharm is set to enhance its position in the French market by appointing Pierre-Hervé Brun as general manager of its French affiliate. The firm has also strengthened its international identity by rebranding its Spanish subsidiary Qualigen to Neuraxpharm Spain.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.